BCG vaccine immunity against human tuberculosis. The BCG vaccine can be anywhere from 0 to 80% effective in preventing tuberculosis for a duration of 15 years; however, its protective effect appears to vary according to geography and the lab in which the vaccine strain was grown. A number of different companies make BCG, sometimes using different genetic strains of the bacterium. This may result in different product characteristics. OncoTICE, used for bladder instillation for bladder cancer, was developed by Organon Laboratories (since acquired by Schering-Plough, and in turn acquired by Merck & Co.). Pacis BCG, made from the Montréal (Institut Armand-Frappier) strain,
Inoculation theory are more likely to be inoculated by issue/advocacy messages. They use Mobil Oil's issue/advocacy campaign to test the hypotheses. The first hypothesis was supported by the data. There was a significant effect provided by inoculation. Additionally, H1 showed that issue/advocacy inoculation messages and attack messages vary in effectiveness depending on the content. The result was also noted in the results of H2, which were also supported by the results. Finally, the results indicated that political views play a role in the effectiveness of the campaigns. Thus, confirming H3, that conservatives are easier to inoculate. They also posed a research question